Does synthetic biology hold the key to unlocking solid tumors for cell and gene therapy?

While cellular immunotherapy holds promise in treating liquid and potentially solid tumors, considerable challenges prevent these therapies from being wholly effective. David McCall, Senior Editor at BioInsights, speaks with Ming-Ru Wu, Assistant Professor, Dana-Farber Cancer Institute and Harvard Medical School, about his work in employing synthetic biology principles, AI, high-throughput screening, and multiomics tools to design a new wave of immunotherapies with the potential to advance the field into the mainstream of cancer therapy.

Please enter your email to access content Read now